Anavex Life Sciences Corp (AVXL)

[ExtremelyBullishZig]

And another thing that I pointed out about a year ago. There was a point in time when the company was very cocky about no patent issues and mention that the mono therapy was working just as good as the combo therapy. You will notice when comparing patent application rejections and then final rejections to the timing of our silence in news... that they happen at the same time.

When they didn't get those patents granted and had to even go through a special program after final rejection to get the combo patent allowance it has extended our silence. Now with the required Declaration of oath and other little things making it so we will barely squeak by with patent approval, you will start to notice all the news and data pouring out. All that news will probably show that donepezil is not necessarily needed. They will say... There is synergy between donepezil and a 273, but when using a high dose of 273 alone alone if our outweighs the synergy benefits. This way the patent claims are satisfied and the mono therapy is the winner.